Healthcare Industry News: Elixir Pharmaceuticals
News Release - November 2, 2006
Cohera Medical, Inc. Announces Dr. Doros Platika Elected as Chairman of the Board of DirectorsPITTSBURGH, Nov. 2 (HSMN NewsFeed) -- Cohera Medical, Inc., a rapidly growing medical device company that intends to commercialize novel surgical adhesives, announced today that Dr. Doros Platika will be joining the Board of Directors as Chairman effective December 1, 2006.
Dr. Doros Platika is currently President and Chief Executive Officer of the Pittsburgh Life Sciences Greenhouse and Chairman, Chief Executive Officer, and Co-Founder of the Supercentenarian Research Foundation. He joined the PLSG from Boston-based MPM Capital, a leading national venture capital firm focused on the life sciences. Before that, he had demonstrated an ability to develop and grow life science companies, following 11 years of pragmatic clinical medicine experience. Dr. Platika was Chairman, President and CEO of Cambridge-based Centagenetix, Inc., which was acquired by Elixir Pharmaceuticals in February 2003. Other experience includes service as: Chairman, President, CEO and founder of Cambridge-based Curis, Inc.; President and CEO of Cambridge-based Ontogeny, Inc.; and Executive Vice President of research and development with Columbus, Ohio-based Progenitor Inc. He earned his B.A. at Reed College, majoring in Biology and Psychology. He received his M.D. from the State University of New York at Stony Brook, School of Medicine.
"Dr. Platika has been a great supporter of Cohera Medical and someone who is very interested in Life Sciences' companies becoming a success in the region. Doros brings many years of experience and wisdom to the Chairman position and I know the company will benefit with his leadership," said Patrick Daly, President and CEO of Cohera Medical.
Dr. Platika completed residencies in both medicine and neurology at the Massachusetts General Hospital, where he served as a chief resident. He completed his post-doctoral study at the Massachusetts Institute of Technology's Whitehead Institute in gene therapy, and at Massachusetts General Hospital, Harvard Medical School, in developmental biology. He has also served on the faculty of both Harvard Medical School and the Albert Einstein College of Medicine.
"We couldn't be more delighted by Doros' decision to join our board as Chairman," said Jay Kern, Managing Director of Reynolds, Dewitt & Co., and a director on the Cohera Board. "In light of his wealth of relevant experience and terrific track record of success in life sciences, his decision serves to confirm the exciting prospects for our company."
"I welcome the combination of his medical background and entrepreneurial experience at this stage of development for Cohera," said Jerry McGinnis, Chairman of Respironics, Inc., and a director on the Cohera Board.
About Cohera Medical, Inc.
Cohera Medical, Inc. is a Pittsburgh-based medical device company that intends to commercialize biodegradable surgical adhesives. Cohera's first product, TissuGlu(TM), under development, is an easy-to use, strong and resorbable polymer adhesive aimed at fulfilling the market demand for a strong, safe tissue adhesive that will improve the wound closure process by positioning tissues for optimal healing while minimizing fluid accumulation. The flexibility of Cohera's proprietary chemistry supports a family of products with differences in strength, set time and resorption rate that Cohera believes will meet the varying specific demands and requirements of the market.
Source: Cohera Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.